The former research director of the Medical Oncology Service at the Ramon y Cajal Hospital in Madrid has led more than 100 international clinical trials and has published papers in more than 150 scientific journals
-
Dr. Grande is also a founding partner of the Spanish Group of Orphan and Rare Tumors (GETHI), member of the board of directors of the Spanish Group of Neuroendocrine Tumors (GETNE) and advisor to the Spanish Agency for Medicines (Aemps), among other positions.
After almost a decade working at the Ramon y Cajal University Hospital in Madrid as director of Clinical and Translational Research in the Medical Oncology Service, Dr. Enrique Grande has just been appointed head of the Medical Oncology service at MD Anderson Cancer Center Madrid.
Given his experience - this specialist was the creator of the Phase I Studies Unit of oncological drugs at the Ramon y Cajal Hospital, he encouraged the development of joint urology and oncology consultations, and contributed decisively to the fact that the hospital was designated as a national reference in the treatment of renal and germinal tumors, Dr. Grande will not only be in charge of directing the oncology area of the center, but will also be responsible for two areas of great relevance for MD Anderson Madrid: the areas of research and treatment of genitourinary and endocrine tumors.
"It is an honor and a great responsibility for me to be able to work in a center of excellence in cancer treatment such as MD Anderson Madrid, where some of the most outstanding experts in this area work," said Dr. Grande, who has also expressed his satisfaction at being able to head the research area of the center, which for him is "the only way to advance in the treatment of patients with cancer."
Currently, Dr. Grande is also a member of the board of directors of the Spanish Group of Orphan and Rare Tumors (GETHI), an institution of which he is a founding partner, and of the Spanish Group of Neuroendocrine Tumors (GETNE). A work that he combines with an advisory role in the Spanish Agency of Medicine (Aemps) and his participation as an active member in the Spanish Group of Genitourinary Tumors (SOGUG), where he collaborates with the working committee for the management of renal tumors, and with the Stem Cell Study Group in Oncology (GESTO), where he serves as scientific secretary.
In addition, Dr. Grande has collaborated on more than one hundred international clinical trials, has published papers in more than 150 scientific journals and is associate editor of the journals Clinical and Traslational Oncology, Future Oncology, World Journal Clinical Oncology and the Mexican Gazette of Oncology.